SCHEMBL3134440

SCHEMBL3134440

CCN1C(=O)/C(=C/c2ccc(-c3ccccc3O)o2)SC1=S

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 2/20 0.74
STAT3 P40763 1/20 0.64
MAP3K5 Q99683 7/20 0.62
ENPP2 Q13822 1/20 0.61
SYK P43405 1/20 0.59
PIK3CA P42336 1/20 0.56
PIK3CB P42338 1/20 0.56
PIK3CG P48736 1/20 0.56
ALDH1A1 P00352 3/20 0.53
MAPT P10636 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.53
POLB P06746 1/20 0.53
RAB9A P51151 1/20 0.53
ALOX12 P18054 1/20 0.53
RECQL P46063 1/20 0.53
MCL1 Q07820 1/20 0.53
PTPN22 Q9Y2R2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3134450 1.00 TNFRSF1A (0.74) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3134456 1.00 TNFRSF1A (0.74) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3135778 0.88 TNFRSF1A (0.73) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3126751 0.88 MAP3K5 (0.76) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3128897 0.88 MAP3K5 (0.76) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3135786 0.88 TNFRSF1A (0.73) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3128904 0.88 MAP3K5 (0.76) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3136515 0.88 MAP3K5 (0.76) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3136503 0.88 MAP3K5 (0.76) TNFRSF1ASTAT3MAP3K5ENPP2SYK
SCHEMBL3135769 0.88 TNFRSF1A (0.73) TNFRSF1ASTAT3MAP3K5ENPP2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO claimed
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 TNFRSF1A 2355/4885STAT3 4654/4885MAP3K5 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.